https://ctep.cancer.gov/protocolDevelopment/docs/recist_guideline.pdf

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

WHO CLASSIFICATION OF TUMOURS OF HAEMATOPOIETIC AND LYMPHOID TISSUES , WHO CLASSIFICATION OF TUMOURS OF HAEMATOPOIETIC AND LYMPHOID TISSUES , کتابخانه مرکزی دانشگاه علوم پزشکی تهران

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

Immune checkpoints refer to the plethora of inhibitory pathways that are crucial to maintaining self-tolerance. Tumour cells induce immune checkpoints to evade immunosurveillance. This Review discusses the progress in targeting immune checkpoints, the considerations for combinatorial therapy and the potential for additional immune-checkpoint targets.

/pdf/the-blockade-of-immune-checkpoints-in-cancer-immunotherapy-j2cp4ba5s9.pdf

The blockade of immune checkpoints in cancer immunotherapy

12 Pathology and Microbiology, and 13 Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed that this variability in natural history reflects unrecognized molecular heterogeneity in the tumours. Using DNA microarrays, we have conducted a systematic characterization of gene expression in B-cell malignancies. Here we show that there is diversity in gene expression among the tumours of DLBCL patients, apparently reflecting the variation in tumour proliferation rate, host response and differentiation state of the tumour. We identified two molecularly distinct forms of DLBCL which had gene expression patterns indicative of different stages of B-cell differentiation. One type expressed genes characteristic of germinal centre B cells ('germinal centre B-like DLBCL'); the second type expressed genes normally induced during in vitro activation of peripheral blood B cells ('activated B-like DLBCL'). Patients with germinal centre B-like DLBCL had a significantly better overall survival than those with activated B-like DLBCL. The molecular classification of tumours on the basis of gene expression can thus identify previously undetected and clinically significant subtypes of cancer.

/pdf/distinct-types-of-diffuse-large-b-cell-lymphoma-identified-508avrqemv.pdf

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

We introduce CIBERSORT, a method for characterizing cell composition of complex tissues from their gene expression profiles When applied to enumeration of hematopoietic subsets in RNA mixtures from fresh, frozen and fixed tissues, including solid tumors, CIBERSORT outperformed other methods with respect to noise, unknown mixture content and closely related cell types CIBERSORT should enable large-scale analysis of RNA mixtures for cellular biomarkers and therapeutic targets (http://cibersortstanfordedu/)

/pdf/robust-enumeration-of-cell-subsets-from-tissue-expression-2prfdfkgtp.pdf

Robust enumeration of cell subsets from tissue expression profiles

/pdf/an-international-real-world-analysis-of-relapsed-refractory-3mb1fu7f.pdf

An International Real-World Analysis of Relapsed/Refractory Lymphoma Occurring During Pregnancy.

https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2023010037/2050552/bloodadvances.2023010037.pdf

The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network.

Enrichment of innate immune cells from PBMC followed by triple cytokine activation for adoptive immunotherapy.

The non-Hodgkin’s lymphomas (NHL) represent a diverse group of neoplasms with many different clinical presentations, associated laboratory abnormalities, responsiveness to treatment, and clinical outcome. The cell of origin and stage of maturation arrest prior to uncontrolled proliferation are important to the understanding of this diversity (Table 47.1). In the USA, the incidence of NHL steadily increases from childhood through age 80 years; unlike Hodgkin’s disease, no peak incidence exists for young adults. NHL is the fifth most common malignancy in men and women, respectively, and is among the most rapidly increasing malignancies [1]. They represent the seventh most common cause of death from cancer in the USA, with the age-adjusted incidence being about three times that of Hodgkin’s disease [1]. The incidence of non-Hodgkin’s lymphoma is twice as frequent among whites as blacks, and there is an almost 50 % increase in presentation in males compared with females. The reason for this gender and race predominance is unknown; however, it may reflect a different pattern of occupational exposure or a difference in the immune status of males compared with females. Links among agricultural work (organochlorine-based pesticides), wood products, and organic solvents have been established [2].

Julie M. Vose

Papers

An International Real-World Analysis of Relapsed/Refractory Lymphoma Occurring During Pregnancy.

The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network.

Enrichment of innate immune cells from PBMC followed by triple cytokine activation for adoptive immunotherapy.

Diagnosis and Treatment of Non-Hodgkin’s Lymphoma of Adults